SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024

PR Newswire

NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders:

The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 8, 2023 and November 28, 2023.

If you suffered a loss on your investment in Eagle Pharmaceuticals, contact us about potential recovery by using the link below. There is no cost or obligation to you.

https://www.wongesq.com/pslra-1/eagle-pharmaceuticals-inc-class-action-submission-form/?prid=66242&wire=4

ABOUT THE ACTION: The class action against Eagle Pharmaceuticals includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company was experiencing slower-thananticipated pull-though from a wholesale customer predominantly due to expiry of inventory; (2) that, as a result, the Company had overstated its revenue; (3) that the Company did not have effective internal controls and procedures over financial reporting as to sales of PEMFEXY, Eagle Pharmaceuticals' metabolic inhibitor product; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE: February 9, 2024

Aggrieved Eagle Pharmaceuticals investors only have until February 9, 2024 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-law-offices-of-vincent-wong-remind-eagle-pharmaceuticals-investors-of-a-lead-plaintiff-deadline-of-february-9-2024-302056549.html

SOURCE The Law Offices of Vincent Wong

Copyright CNW Group 2024

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).